 Brian Freed
Concepts (523)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA-DRB1 Chains | 8 | 2025 | 110 | 1.660 |
Why?
| | T-Lymphocytes | 22 | 2025 | 1997 | 1.360 |
Why?
| | Epitopes | 4 | 2016 | 473 | 1.160 |
Why?
| | HLA Antigens | 9 | 2024 | 240 | 0.860 |
Why?
| | Genetic Predisposition to Disease | 6 | 2016 | 2399 | 0.840 |
Why?
| | Lymphocyte Activation | 19 | 2006 | 1133 | 0.820 |
Why?
| | Arthritis, Rheumatoid | 4 | 2025 | 1180 | 0.800 |
Why?
| | Interleukin-2 | 16 | 2005 | 440 | 0.740 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2022 | 124 | 0.670 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1751 | 0.670 |
Why?
| | Hydroquinones | 6 | 2003 | 22 | 0.670 |
Why?
| | Kidney Transplantation | 20 | 2019 | 712 | 0.650 |
Why?
| | Back Pain | 1 | 2021 | 52 | 0.640 |
Why?
| | HLA-B Antigens | 3 | 2024 | 58 | 0.620 |
Why?
| | HLA-DR Antigens | 5 | 2020 | 220 | 0.570 |
Why?
| | Alleles | 8 | 2025 | 896 | 0.540 |
Why?
| | Tars | 3 | 2006 | 5 | 0.530 |
Why?
| | Graft Rejection | 14 | 2019 | 521 | 0.530 |
Why?
| | Acrolein | 2 | 2007 | 22 | 0.480 |
Why?
| | Immunosuppressive Agents | 13 | 2017 | 838 | 0.470 |
Why?
| | Vimentin | 2 | 2016 | 54 | 0.460 |
Why?
| | Cyclosporins | 11 | 1991 | 71 | 0.460 |
Why?
| | Peptides, Cyclic | 2 | 2016 | 273 | 0.410 |
Why?
| | Catechols | 4 | 2003 | 14 | 0.410 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2022 | 202 | 0.390 |
Why?
| | Peptides | 2 | 2016 | 998 | 0.390 |
Why?
| | Transplantation, Haploidentical | 2 | 2024 | 23 | 0.390 |
Why?
| | Tissue Donors | 6 | 2018 | 420 | 0.370 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2022 | 364 | 0.370 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 266 | 0.360 |
Why?
| | Fetal Blood | 6 | 2024 | 327 | 0.360 |
Why?
| | Smoking | 5 | 2011 | 1477 | 0.360 |
Why?
| | DNA | 7 | 2007 | 1437 | 0.350 |
Why?
| | Cord Blood Stem Cell Transplantation | 5 | 2016 | 103 | 0.350 |
Why?
| | Immune Tolerance | 4 | 2025 | 385 | 0.340 |
Why?
| | Smoke | 5 | 2007 | 148 | 0.340 |
Why?
| | B-Lymphocytes | 7 | 2021 | 872 | 0.330 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 849 | 0.330 |
Why?
| | Double-Blind Method | 2 | 2024 | 2064 | 0.330 |
Why?
| | Humans | 93 | 2024 | 145763 | 0.320 |
Why?
| | Ribonucleotide Reductases | 2 | 2000 | 29 | 0.300 |
Why?
| | Graft Survival | 9 | 2017 | 519 | 0.300 |
Why?
| | Arachis | 1 | 2010 | 108 | 0.300 |
Why?
| | Immunoglobulin E | 1 | 2010 | 315 | 0.280 |
Why?
| | Immunoglobulin G | 4 | 2013 | 892 | 0.280 |
Why?
| | Peanut Hypersensitivity | 1 | 2010 | 143 | 0.280 |
Why?
| | Cells, Cultured | 11 | 2019 | 4151 | 0.260 |
Why?
| | Lymphocytes | 3 | 2013 | 376 | 0.260 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 23 | 0.260 |
Why?
| | Isoantibodies | 3 | 2017 | 57 | 0.250 |
Why?
| | Disease Models, Animal | 5 | 2021 | 4568 | 0.240 |
Why?
| | Plants, Toxic | 3 | 2000 | 18 | 0.240 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2016 | 1146 | 0.230 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2006 | 53 | 0.230 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2006 | 49 | 0.230 |
Why?
| | Immune System | 2 | 2021 | 180 | 0.230 |
Why?
| | Histocompatibility Testing | 7 | 2019 | 123 | 0.220 |
Why?
| | Flow Cytometry | 5 | 2016 | 1165 | 0.220 |
Why?
| | Tuberculosis | 2 | 2023 | 284 | 0.220 |
Why?
| | Mycobacterium tuberculosis | 2 | 2023 | 318 | 0.220 |
Why?
| | Enzyme Inhibitors | 2 | 2000 | 821 | 0.220 |
Why?
| | Ethylmaleimide | 3 | 1991 | 18 | 0.220 |
Why?
| | Mental Disorders | 1 | 2014 | 1169 | 0.220 |
Why?
| | Antibodies | 3 | 2019 | 397 | 0.220 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 699 | 0.210 |
Why?
| | Haplotypes | 3 | 2014 | 500 | 0.210 |
Why?
| | Ganciclovir | 4 | 1997 | 53 | 0.210 |
Why?
| | Cell Line | 10 | 2016 | 2823 | 0.200 |
Why?
| | Cytomegalovirus Infections | 5 | 1997 | 206 | 0.200 |
Why?
| | Gene Frequency | 3 | 2019 | 489 | 0.200 |
Why?
| | Glutamic Acid | 1 | 2025 | 255 | 0.190 |
Why?
| | Islets of Langerhans | 3 | 1994 | 847 | 0.190 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2014 | 3937 | 0.190 |
Why?
| | HLA-A Antigens | 1 | 2022 | 52 | 0.180 |
Why?
| | HLA-C Antigens | 1 | 2022 | 37 | 0.180 |
Why?
| | Collagen | 1 | 2025 | 457 | 0.180 |
Why?
| | Interferon-gamma | 3 | 2005 | 784 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2005 | 1217 | 0.180 |
Why?
| | Cigarette Smoking | 1 | 2023 | 102 | 0.180 |
Why?
| | Histocompatibility Antigens | 1 | 2022 | 102 | 0.180 |
Why?
| | Protein Binding | 3 | 2016 | 2240 | 0.170 |
Why?
| | Cyclosporine | 5 | 1998 | 256 | 0.170 |
Why?
| | In Vitro Techniques | 9 | 2005 | 1049 | 0.170 |
Why?
| | Enoxaparin | 1 | 2022 | 68 | 0.170 |
Why?
| | Receptors, KIR | 2 | 2022 | 118 | 0.170 |
Why?
| | Central Tolerance | 1 | 2021 | 10 | 0.170 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2021 | 41 | 0.160 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1482 | 0.160 |
Why?
| | Receptors, CXCR4 | 1 | 2021 | 91 | 0.160 |
Why?
| | Transplantation, Homologous | 9 | 2019 | 419 | 0.160 |
Why?
| | HLA-DRB4 Chains | 1 | 2020 | 6 | 0.160 |
Why?
| | Heterografts | 1 | 2021 | 143 | 0.160 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2601 | 0.160 |
Why?
| | Evolution, Molecular | 1 | 2024 | 494 | 0.160 |
Why?
| | Receptors, Interleukin-2 | 5 | 2003 | 64 | 0.160 |
Why?
| | Mice | 18 | 2025 | 18355 | 0.160 |
Why?
| | Brain Ischemia | 1 | 2024 | 359 | 0.160 |
Why?
| | Cell Division | 4 | 1997 | 757 | 0.160 |
Why?
| | Nickel | 1 | 2020 | 62 | 0.150 |
Why?
| | Trace Elements | 1 | 2020 | 52 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2020 | 198 | 0.150 |
Why?
| | Bias | 1 | 2021 | 197 | 0.150 |
Why?
| | Receptors, Antigen, B-Cell | 2 | 2021 | 130 | 0.150 |
Why?
| | alpha 1-Antitrypsin | 1 | 2020 | 104 | 0.150 |
Why?
| | Transcription Factors | 2 | 2005 | 1736 | 0.150 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2019 | 17 | 0.150 |
Why?
| | Cell Cycle Proteins | 1 | 2003 | 630 | 0.140 |
Why?
| | Immunotherapy | 2 | 2021 | 667 | 0.140 |
Why?
| | Vascular System Injuries | 1 | 2019 | 81 | 0.140 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2020 | 70 | 0.140 |
Why?
| | Adrenocortical Carcinoma | 1 | 2020 | 72 | 0.140 |
Why?
| | Animals | 26 | 2025 | 38097 | 0.140 |
Why?
| | Unrelated Donors | 2 | 2024 | 39 | 0.140 |
Why?
| | Tacrolimus | 2 | 2017 | 196 | 0.140 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 735 | 0.140 |
Why?
| | Insulin | 3 | 1994 | 2516 | 0.140 |
Why?
| | HEK293 Cells | 2 | 2022 | 741 | 0.140 |
Why?
| | Transcription, Genetic | 2 | 2003 | 1454 | 0.130 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 35 | 0.130 |
Why?
| | Herpesvirus 4, Human | 1 | 2018 | 172 | 0.130 |
Why?
| | Hydrogen Peroxide | 3 | 1988 | 335 | 0.130 |
Why?
| | Cell Transplantation | 1 | 1997 | 39 | 0.130 |
Why?
| | Donor Selection | 1 | 2018 | 79 | 0.130 |
Why?
| | Hypersensitivity | 1 | 2020 | 254 | 0.130 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 101 | 0.130 |
Why?
| | Antiviral Agents | 3 | 2020 | 769 | 0.130 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 218 | 0.130 |
Why?
| | Proinsulin | 1 | 1997 | 54 | 0.130 |
Why?
| | Amino Acid Sequence | 4 | 2016 | 2131 | 0.120 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 376 | 0.120 |
Why?
| | Benzoquinones | 1 | 1997 | 46 | 0.120 |
Why?
| | Mice, Inbred BALB C | 5 | 2021 | 1261 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2018 | 228 | 0.120 |
Why?
| | Transplantation Conditioning | 1 | 2018 | 191 | 0.120 |
Why?
| | Complement System Proteins | 1 | 2019 | 314 | 0.120 |
Why?
| | Interleukin-1 | 1 | 2000 | 961 | 0.120 |
Why?
| | Genetic Variation | 2 | 2015 | 976 | 0.120 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2016 | 25 | 0.120 |
Why?
| | HLA-DQ beta-Chains | 1 | 2016 | 58 | 0.120 |
Why?
| | Dextrans | 1 | 2016 | 84 | 0.120 |
Why?
| | Collagen Type II | 1 | 2016 | 53 | 0.120 |
Why?
| | Autoantibodies | 4 | 2021 | 1509 | 0.120 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 195 | 0.120 |
Why?
| | Cytotoxicity, Immunologic | 3 | 2012 | 224 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 218 | 0.120 |
Why?
| | Female | 29 | 2024 | 79035 | 0.120 |
Why?
| | Genotype | 3 | 2022 | 1857 | 0.110 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2016 | 387 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1150 | 0.110 |
Why?
| | Adult | 19 | 2024 | 40872 | 0.110 |
Why?
| | Resting Phase, Cell Cycle | 2 | 2006 | 16 | 0.110 |
Why?
| | Protein Kinase C | 1 | 1996 | 251 | 0.110 |
Why?
| | Genetic Therapy | 1 | 1997 | 316 | 0.110 |
Why?
| | Tobacco Smoke Pollution | 1 | 1997 | 227 | 0.110 |
Why?
| | Methylprednisolone | 3 | 1991 | 59 | 0.110 |
Why?
| | Retrospective Studies | 10 | 2024 | 17325 | 0.110 |
Why?
| | Stroke | 1 | 2024 | 1271 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 469 | 0.110 |
Why?
| | G1 Phase | 2 | 2006 | 65 | 0.110 |
Why?
| | Clonal Anergy | 1 | 1994 | 52 | 0.110 |
Why?
| | Kidney Failure, Chronic | 2 | 2017 | 599 | 0.100 |
Why?
| | Tumor Cells, Cultured | 4 | 2020 | 887 | 0.100 |
Why?
| | Autoimmunity | 2 | 2021 | 933 | 0.100 |
Why?
| | Immunoglobulin Isotypes | 1 | 2013 | 36 | 0.100 |
Why?
| | Lymphocyte Culture Test, Mixed | 7 | 1996 | 49 | 0.100 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 442 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 992 | 0.100 |
Why?
| | Endothelial Cells | 1 | 2019 | 877 | 0.100 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2013 | 24 | 0.100 |
Why?
| | Cell Cycle | 3 | 2006 | 598 | 0.100 |
Why?
| | Models, Biological | 1 | 2020 | 1764 | 0.100 |
Why?
| | C-Reactive Protein | 2 | 1987 | 423 | 0.100 |
Why?
| | Radioimmunoassay | 5 | 1990 | 165 | 0.090 |
Why?
| | Models, Animal | 2 | 2013 | 392 | 0.090 |
Why?
| | Male | 23 | 2024 | 73003 | 0.090 |
Why?
| | Dried Blood Spot Testing | 1 | 2013 | 126 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2013 | 132 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 936 | 0.090 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 54 | 0.090 |
Why?
| | Pulmonary Fibrosis | 1 | 2016 | 395 | 0.090 |
Why?
| | Leukemia L1210 | 1 | 1992 | 7 | 0.090 |
Why?
| | Indoles | 1 | 1996 | 507 | 0.090 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 334 | 0.090 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2012 | 334 | 0.090 |
Why?
| | Chagas Disease | 1 | 2012 | 42 | 0.090 |
Why?
| | Islets of Langerhans Transplantation | 1 | 1992 | 71 | 0.090 |
Why?
| | Middle Aged | 13 | 2024 | 36302 | 0.090 |
Why?
| | Beryllium | 2 | 2005 | 161 | 0.090 |
Why?
| | Bronchiolitis Obliterans | 1 | 2012 | 61 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2025 | 2191 | 0.090 |
Why?
| | Blood Specimen Collection | 1 | 2011 | 37 | 0.090 |
Why?
| | Lung | 4 | 2007 | 4116 | 0.080 |
Why?
| | Interleukin Receptor Common gamma Subunit | 1 | 2011 | 14 | 0.080 |
Why?
| | Blood Banks | 1 | 2011 | 50 | 0.080 |
Why?
| | Maleimides | 1 | 1991 | 21 | 0.080 |
Why?
| | Transplantation Chimera | 1 | 2011 | 57 | 0.080 |
Why?
| | Calcium | 2 | 1994 | 1191 | 0.080 |
Why?
| | International Cooperation | 1 | 2011 | 197 | 0.080 |
Why?
| | Chromatography, High Pressure Liquid | 7 | 2005 | 592 | 0.080 |
Why?
| | Child, Preschool | 6 | 2014 | 11868 | 0.080 |
Why?
| | Postoperative Complications | 5 | 2017 | 2977 | 0.080 |
Why?
| | Receptors, Transferrin | 2 | 2003 | 28 | 0.080 |
Why?
| | Mice, Knockout | 5 | 2021 | 3130 | 0.080 |
Why?
| | Fibroblasts | 2 | 1994 | 1027 | 0.080 |
Why?
| | Spleen | 1 | 2013 | 508 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2019 | 868 | 0.080 |
Why?
| | Serine Endopeptidases | 2 | 2022 | 129 | 0.080 |
Why?
| | Skin Tests | 1 | 2010 | 94 | 0.080 |
Why?
| | Mitogens | 2 | 1988 | 55 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2013 | 509 | 0.080 |
Why?
| | Antibody Formation | 1 | 1991 | 288 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1850 | 0.080 |
Why?
| | Siblings | 1 | 2010 | 196 | 0.080 |
Why?
| | Jurkat Cells | 2 | 2000 | 115 | 0.070 |
Why?
| | Base Sequence | 3 | 2012 | 2171 | 0.070 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 435 | 0.070 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1430 | 0.070 |
Why?
| | Nicotine | 2 | 2023 | 331 | 0.070 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2007 | 23 | 0.070 |
Why?
| | Cesarean Section | 1 | 2011 | 230 | 0.070 |
Why?
| | Disease Susceptibility | 1 | 2011 | 344 | 0.070 |
Why?
| | HLA-DQ Antigens | 2 | 2000 | 174 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1969 | 0.070 |
Why?
| | Survival Rate | 5 | 2017 | 2094 | 0.070 |
Why?
| | Immunoglobulins, Intravenous | 3 | 1995 | 133 | 0.070 |
Why?
| | Cricetinae | 3 | 1994 | 305 | 0.070 |
Why?
| | Cell Survival | 3 | 1997 | 1103 | 0.070 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2016 | 692 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2012 | 332 | 0.070 |
Why?
| | Phytohemagglutinins | 4 | 1991 | 29 | 0.070 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 153 | 0.070 |
Why?
| | Allografts | 2 | 2019 | 152 | 0.070 |
Why?
| | Adolescent | 7 | 2014 | 22573 | 0.070 |
Why?
| | Research Design | 1 | 2014 | 1139 | 0.070 |
Why?
| | Molecular Sequence Data | 3 | 2012 | 2883 | 0.070 |
Why?
| | Amino Acids | 1 | 2011 | 519 | 0.070 |
Why?
| | Anemia, Sickle Cell | 1 | 2012 | 318 | 0.070 |
Why?
| | Mice, Nude | 2 | 2020 | 680 | 0.070 |
Why?
| | Genetic Linkage | 2 | 2006 | 273 | 0.070 |
Why?
| | Mice, Inbred NOD | 2 | 2021 | 616 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2019 | 923 | 0.060 |
Why?
| | Isoantigens | 1 | 1987 | 17 | 0.060 |
Why?
| | Cell Differentiation | 4 | 2021 | 2050 | 0.060 |
Why?
| | Transcription Factor AP-1 | 1 | 2007 | 79 | 0.060 |
Why?
| | NFATC Transcription Factors | 1 | 2007 | 94 | 0.060 |
Why?
| | Cloning, Molecular | 2 | 1998 | 538 | 0.060 |
Why?
| | Kidney Function Tests | 2 | 2017 | 156 | 0.060 |
Why?
| | Aged | 6 | 2024 | 26215 | 0.060 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5428 | 0.060 |
Why?
| | Aldehydes | 1 | 2007 | 140 | 0.060 |
Why?
| | HLA-B15 Antigen | 1 | 2006 | 12 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2006 | 88 | 0.060 |
Why?
| | Muromonab-CD3 | 2 | 1997 | 6 | 0.060 |
Why?
| | Lung Diseases | 2 | 2006 | 782 | 0.060 |
Why?
| | Sequence Homology | 1 | 2006 | 43 | 0.060 |
Why?
| | Butylated Hydroxytoluene | 1 | 2006 | 37 | 0.060 |
Why?
| | Bone Marrow | 2 | 2021 | 307 | 0.060 |
Why?
| | Microspheres | 1 | 2006 | 142 | 0.060 |
Why?
| | Prognosis | 4 | 2017 | 4329 | 0.060 |
Why?
| | HLA-DP Antigens | 1 | 2005 | 32 | 0.060 |
Why?
| | Cysteine | 1 | 2007 | 211 | 0.060 |
Why?
| | Phenotype | 3 | 2021 | 3170 | 0.060 |
Why?
| | Autoantigens | 2 | 2021 | 427 | 0.060 |
Why?
| | Phospholipases A | 1 | 2006 | 97 | 0.060 |
Why?
| | Arginine | 1 | 2007 | 264 | 0.060 |
Why?
| | Cell Proliferation | 2 | 2020 | 2514 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 158 | 0.060 |
Why?
| | Transfection | 2 | 1998 | 927 | 0.060 |
Why?
| | Phenols | 1 | 2006 | 106 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2913 | 0.060 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2005 | 125 | 0.060 |
Why?
| | Child | 5 | 2014 | 22739 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2005 | 83 | 0.050 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 37 | 0.050 |
Why?
| | Chemokines, CXC | 1 | 2004 | 68 | 0.050 |
Why?
| | Treatment Outcome | 5 | 2024 | 11793 | 0.050 |
Why?
| | Acetylcysteine | 1 | 2005 | 139 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2005 | 208 | 0.050 |
Why?
| | Skin Transplantation | 1 | 2025 | 85 | 0.050 |
Why?
| | Structure-Activity Relationship | 3 | 1991 | 563 | 0.050 |
Why?
| | Amino Acid Substitution | 1 | 2025 | 302 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2011 | 3634 | 0.050 |
Why?
| | Agglutination | 2 | 1997 | 5 | 0.050 |
Why?
| | Reoperation | 3 | 1998 | 637 | 0.050 |
Why?
| | Young Adult | 3 | 2024 | 14251 | 0.050 |
Why?
| | Pandemics | 2 | 2024 | 1711 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2025 | 298 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 6085 | 0.050 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2003 | 36 | 0.050 |
Why?
| | Berylliosis | 1 | 2005 | 202 | 0.050 |
Why?
| | Concanavalin A | 3 | 1988 | 72 | 0.050 |
Why?
| | Lectins, C-Type | 1 | 2003 | 59 | 0.050 |
Why?
| | E2F Transcription Factors | 1 | 2003 | 65 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 615 | 0.050 |
Why?
| | Glomerular Filtration Rate | 2 | 2017 | 765 | 0.050 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2003 | 104 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 376 | 0.050 |
Why?
| | Mesocricetus | 2 | 1992 | 52 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2015 | 322 | 0.050 |
Why?
| | Risk Factors | 6 | 2017 | 10917 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2004 | 308 | 0.050 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 396 | 0.050 |
Why?
| | Cell Line, Transformed | 2 | 1992 | 138 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2005 | 337 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2933 | 0.050 |
Why?
| | Biomarkers | 2 | 2019 | 4302 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2005 | 611 | 0.040 |
Why?
| | Drug Synergism | 2 | 1996 | 354 | 0.040 |
Why?
| | Cell Communication | 2 | 2013 | 327 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 1987 | 177 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2003 | 169 | 0.040 |
Why?
| | Neutrophils | 2 | 2005 | 1125 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2022 | 272 | 0.040 |
Why?
| | Apoptosis | 2 | 2020 | 2443 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 2 | 2016 | 420 | 0.040 |
Why?
| | Leukemia | 2 | 2012 | 246 | 0.040 |
Why?
| | Antioxidants | 2 | 2006 | 550 | 0.040 |
Why?
| | Chimerism | 1 | 2021 | 35 | 0.040 |
Why?
| | Iron Chelating Agents | 1 | 2000 | 17 | 0.040 |
Why?
| | Biopsy | 2 | 2019 | 1082 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 78 | 0.040 |
Why?
| | Cell Separation | 2 | 2011 | 306 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2001 | 179 | 0.040 |
Why?
| | RNA | 2 | 1997 | 912 | 0.040 |
Why?
| | Ganglionic Stimulants | 1 | 2000 | 15 | 0.040 |
Why?
| | Kidney | 4 | 2019 | 1496 | 0.040 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 78 | 0.040 |
Why?
| | Virus Internalization | 1 | 2020 | 65 | 0.040 |
Why?
| | Free Radicals | 1 | 2000 | 105 | 0.040 |
Why?
| | Leukocyte Elastase | 1 | 2020 | 75 | 0.040 |
Why?
| | Dimerization | 1 | 2000 | 189 | 0.040 |
Why?
| | Blotting, Western | 2 | 2004 | 1184 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1478 | 0.040 |
Why?
| | Biological Evolution | 1 | 2024 | 468 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 411 | 0.040 |
Why?
| | Extracellular Traps | 1 | 2020 | 52 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 369 | 0.040 |
Why?
| | Ligands | 1 | 2022 | 668 | 0.040 |
Why?
| | Antithrombins | 1 | 2020 | 71 | 0.040 |
Why?
| | Tyrosine | 1 | 2000 | 217 | 0.040 |
Why?
| | Nephelometry and Turbidimetry | 2 | 2013 | 15 | 0.040 |
Why?
| | Antigens, CD | 1 | 2003 | 558 | 0.040 |
Why?
| | Arthroplasty, Replacement | 1 | 2020 | 47 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 322 | 0.040 |
Why?
| | Luminescent Measurements | 2 | 2013 | 75 | 0.040 |
Why?
| | Inflammation | 3 | 2006 | 2883 | 0.040 |
Why?
| | Granuloma, Respiratory Tract | 1 | 1999 | 13 | 0.040 |
Why?
| | Receptors, Cytokine | 1 | 1999 | 36 | 0.040 |
Why?
| | Cytokines | 1 | 2007 | 2069 | 0.040 |
Why?
| | Xenobiotics | 1 | 1999 | 30 | 0.040 |
Why?
| | Steroid 21-Hydroxylase | 1 | 1999 | 27 | 0.040 |
Why?
| | Receptors, Interferon | 1 | 1999 | 60 | 0.040 |
Why?
| | Addison Disease | 1 | 1999 | 38 | 0.040 |
Why?
| | Viral Tropism | 1 | 2018 | 36 | 0.040 |
Why?
| | Antigens, CD34 | 2 | 2013 | 90 | 0.030 |
Why?
| | Immunoglobulin M | 2 | 1991 | 265 | 0.030 |
Why?
| | Metallothionein | 1 | 1998 | 25 | 0.030 |
Why?
| | Antibodies, Monoclonal | 3 | 1991 | 1505 | 0.030 |
Why?
| | Virus Latency | 1 | 2018 | 90 | 0.030 |
Why?
| | Virus Activation | 1 | 2018 | 94 | 0.030 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 161 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 574 | 0.030 |
Why?
| | Pokeweed Mitogens | 2 | 1988 | 6 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2018 | 71 | 0.030 |
Why?
| | Depression, Chemical | 1 | 1997 | 16 | 0.030 |
Why?
| | Mycophenolic Acid | 1 | 1998 | 119 | 0.030 |
Why?
| | Drug Therapy, Combination | 2 | 1998 | 1043 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2005 | 2805 | 0.030 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 27 | 0.030 |
Why?
| | Acute Lung Injury | 1 | 2020 | 307 | 0.030 |
Why?
| | 3T3 Cells | 1 | 1997 | 156 | 0.030 |
Why?
| | Insulin, Long-Acting | 1 | 1997 | 65 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 478 | 0.030 |
Why?
| | New York | 1 | 1997 | 128 | 0.030 |
Why?
| | Sulfhydryl Compounds | 2 | 1991 | 189 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 132 | 0.030 |
Why?
| | Guanidines | 1 | 1996 | 39 | 0.030 |
Why?
| | Complement Activation | 1 | 2019 | 399 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 90 | 0.030 |
Why?
| | S Phase | 1 | 1996 | 78 | 0.030 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2016 | 47 | 0.030 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2015 | 9 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 221 | 0.030 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2015 | 23 | 0.030 |
Why?
| | Half-Life | 2 | 1996 | 155 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2021 | 6464 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2016 | 255 | 0.030 |
Why?
| | Liver | 3 | 2007 | 1899 | 0.030 |
Why?
| | Desensitization, Immunologic | 1 | 2016 | 89 | 0.030 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 76 | 0.030 |
Why?
| | Cross Reactions | 3 | 1990 | 130 | 0.030 |
Why?
| | Antigens, Viral, Tumor | 1 | 1994 | 7 | 0.030 |
Why?
| | Antigens, CD19 | 1 | 2015 | 128 | 0.030 |
Why?
| | Genetic Loci | 1 | 2016 | 267 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1994 | 149 | 0.030 |
Why?
| | Iron | 1 | 1997 | 359 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2016 | 182 | 0.030 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2007 | 27 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2001 | 1359 | 0.030 |
Why?
| | Mice, Inbred DBA | 2 | 1992 | 182 | 0.020 |
Why?
| | Prevalence | 1 | 2001 | 2874 | 0.020 |
Why?
| | Mortality | 1 | 2016 | 380 | 0.020 |
Why?
| | Thioguanine | 1 | 2013 | 18 | 0.020 |
Why?
| | Cell Adhesion | 1 | 1994 | 451 | 0.020 |
Why?
| | Immunization, Passive | 1 | 1993 | 90 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2013 | 165 | 0.020 |
Why?
| | Umbilical Cord | 1 | 2013 | 93 | 0.020 |
Why?
| | Survivors | 1 | 2016 | 523 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 132 | 0.020 |
Why?
| | Drug Resistance | 1 | 2013 | 145 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 200 | 0.020 |
Why?
| | Survival Analysis | 2 | 2012 | 1378 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2013 | 147 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2024 | 8346 | 0.020 |
Why?
| | Mercaptopurine | 1 | 1991 | 15 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2012 | 171 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2181 | 0.020 |
Why?
| | Mice, Inbred C57BL | 3 | 2011 | 5992 | 0.020 |
Why?
| | Anticoagulants | 1 | 2016 | 748 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3551 | 0.020 |
Why?
| | Lymphoma | 1 | 2012 | 241 | 0.020 |
Why?
| | Signal Transduction | 2 | 2021 | 5223 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2006 | 638 | 0.020 |
Why?
| | Blood Donors | 1 | 2011 | 144 | 0.020 |
Why?
| | Glucose | 1 | 1994 | 1048 | 0.020 |
Why?
| | Methylmannosides | 1 | 1989 | 1 | 0.020 |
Why?
| | Cytochalasins | 1 | 1989 | 3 | 0.020 |
Why?
| | Rosette Formation | 1 | 1989 | 14 | 0.020 |
Why?
| | Colchicine | 1 | 1989 | 21 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1777 | 0.020 |
Why?
| | Fetus | 1 | 2013 | 804 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 380 | 0.020 |
Why?
| | Monocytes | 2 | 1989 | 539 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 2000 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 896 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1992 | 342 | 0.020 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2007 | 20 | 0.020 |
Why?
| | Lipid Peroxides | 1 | 1987 | 10 | 0.020 |
Why?
| | Oligoclonal Bands | 1 | 2007 | 26 | 0.020 |
Why?
| | Interleukin-6 | 1 | 1991 | 779 | 0.020 |
Why?
| | Blood Glucose | 1 | 1997 | 2344 | 0.020 |
Why?
| | DNA Replication | 1 | 1989 | 249 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1987 | 164 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2006 | 39 | 0.020 |
Why?
| | Chemokine CCL8 | 1 | 2006 | 3 | 0.010 |
Why?
| | Monocyte Chemoattractant Proteins | 1 | 2006 | 7 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2123 | 0.010 |
Why?
| | Phospholipases A2 | 1 | 2006 | 79 | 0.010 |
Why?
| | Chemokine CCL2 | 1 | 2006 | 112 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3416 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2005 | 273 | 0.010 |
Why?
| | Age Factors | 1 | 2013 | 3346 | 0.010 |
Why?
| | Cytosol | 1 | 2006 | 213 | 0.010 |
Why?
| | NADPH Dehydrogenase | 1 | 2005 | 6 | 0.010 |
Why?
| | NADH Dehydrogenase | 1 | 2005 | 20 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 1987 | 274 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1987 | 289 | 0.010 |
Why?
| | Chemokine CXCL1 | 1 | 2004 | 76 | 0.010 |
Why?
| | Infant | 3 | 2007 | 10090 | 0.010 |
Why?
| | NADPH Oxidases | 1 | 2005 | 122 | 0.010 |
Why?
| | Translocation, Genetic | 1 | 2005 | 120 | 0.010 |
Why?
| | Mice, Inbred AKR | 1 | 1983 | 35 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 1988 | 1068 | 0.010 |
Why?
| | Leukemia, Lymphoid | 1 | 1983 | 27 | 0.010 |
Why?
| | Leukemia, Experimental | 1 | 1983 | 27 | 0.010 |
Why?
| | Lymphokines | 1 | 1983 | 128 | 0.010 |
Why?
| | Blood Transfusion | 1 | 1987 | 409 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 762 | 0.010 |
Why?
| | Acute Disease | 1 | 2006 | 1036 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1568 | 0.010 |
Why?
| | Necrosis | 1 | 1984 | 244 | 0.010 |
Why?
| | Rats | 3 | 2004 | 5585 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1512 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2002 | 318 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 6032 | 0.010 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2000 | 17 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1991 | 1925 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 11 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | Hematologic Neoplasms | 1 | 2002 | 168 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2002 | 375 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2525 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 263 | 0.010 |
Why?
| | United States | 1 | 2016 | 16123 | 0.010 |
Why?
| | Prospective Studies | 3 | 1996 | 8075 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 7215 | 0.010 |
Why?
| | Azathioprine | 1 | 1998 | 44 | 0.010 |
Why?
| | Incidence | 2 | 1995 | 2933 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2002 | 1115 | 0.010 |
Why?
| | Prednisone | 1 | 1998 | 226 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 1996 | 61 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1996 | 115 | 0.010 |
Why?
| | Risk Assessment | 1 | 2006 | 3752 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 1996 | 197 | 0.010 |
Why?
| | Risk | 1 | 1999 | 923 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 1996 | 301 | 0.010 |
Why?
| | Dogs | 1 | 1996 | 478 | 0.010 |
Why?
| | Blood Group Incompatibility | 1 | 1995 | 21 | 0.010 |
Why?
| | Species Specificity | 2 | 1988 | 546 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 1995 | 168 | 0.010 |
Why?
| | Diabetic Nephropathies | 1 | 1998 | 322 | 0.010 |
Why?
| | ABO Blood-Group System | 1 | 1995 | 58 | 0.010 |
Why?
| | Cadaver | 1 | 1995 | 311 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 1994 | 428 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 117 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 1995 | 674 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2002 | 2393 | 0.000 |
Why?
| | Rats, Inbred SHR | 1 | 1988 | 36 | 0.000 |
Why?
| | Deferoxamine | 1 | 1988 | 27 | 0.000 |
Why?
| | Malondialdehyde | 1 | 1988 | 31 | 0.000 |
Why?
| | Biotransformation | 1 | 1988 | 62 | 0.000 |
Why?
| | Length of Stay | 1 | 1994 | 1350 | 0.000 |
Why?
| | Injections, Subcutaneous | 1 | 1988 | 170 | 0.000 |
Why?
| | Tissue Distribution | 1 | 1988 | 335 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1986 | 27 | 0.000 |
Why?
| | Kidney Medulla | 1 | 1986 | 31 | 0.000 |
Why?
| | Administration, Oral | 1 | 1988 | 867 | 0.000 |
Why?
| | Blood Physiological Phenomena | 1 | 1983 | 12 | 0.000 |
Why?
| | Suppressor Factors, Immunologic | 1 | 1983 | 4 | 0.000 |
Why?
| | Mice, Inbred CBA | 1 | 1983 | 57 | 0.000 |
Why?
| | Kidney Diseases | 1 | 1988 | 426 | 0.000 |
Why?
| | Thymidine | 1 | 1983 | 60 | 0.000 |
Why?
| | Rats, Inbred Strains | 1 | 1983 | 321 | 0.000 |
Why?
|
|
Freed's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|